Show an ad over header. AMP

A coronavirus vaccine is a chance for China to show its scientific muscle

As the global race for a COVID-19 vaccine heats up, the U.S. is looking to prove it can deliver in a national crisis while China is in its own moment to demonstrate its scientific capabilities.

The big picture: Beyond protecting citizens and bolstering the economy, displays of scientific prowess and tilting geopolitics are driving the development of new vaccines and drugs.


China is "very mindful that the eyes of the world are watching them," says virologist Richard Kuhn of Purdue University.

  • "They want to demonstrate that China is not an emerging power, but a power comparable to the U.S.," he adds.

What's happening: Of the 202 COVID-19 vaccines in development around the world, 20 involve teams in China, per the Milken Institute.

  • The Chinese teams are taking several approaches — from traditional ones that use inactivated forms of the virus to spur immunity to more experimental DNA and RNA vaccine platforms that have yet to be approved for human use for any virus.
  • The vaccines from China are in various stages of development, but three — from Sinopharm and Sinovac Biotech — are in phase III human trials.
  • China has controlled the country's outbreak to the point that it has had to look abroad — to Brazil, Indonesia and the UAE, for example — to test the vaccines on a larger scale.
  • It is also, controversially, testing vaccines on members of the military and construction workers traveling overseas.

There's a lot at stake for China in this urgent moment — but also beyond it.

Researchers in the country are pushing scientific boundaries — and at times sparking controversy — in cloning and regenerative medicine, gene editing and other areas of biomedicine.

  • And China has built up its scientific infrastructure and instrumentation, constructing maximum-security biological laboratories, purchasing sophisticated cryo-electron microscopes and running massive numbers of genome sequencers — all powerful tools and major scientific status symbols.
  • Another key prong of the strategy has been attracting researchers trained overseas back to China, says Ray Yip, a former director of the U.S. CDC's office in China.

"China’s part in this is not just the immediate race for the first safe and effective vaccine it's really the culmination of a much longer strategic plan that they have," says David Fidler, an expert on cybersecurity and global health at the Council on Foreign Relations.

The headwinds: Biotech in China faces hurdles, including a continued reliance on Western countries to train researchers, and the common challenge that, even with resources and experience, it is just plain difficult to discover drugs and create vaccines.

And a lack of transparency in the political system can affect the perception of science at home and abroad.

  • Prior to the pandemic, Chinese citizens' trust in their country's vaccine companies was rattled by bribery scandals and problems with ineffective vaccines.
  • In the current pandemic, the Chinese government — from local to central levels — has been criticized for its early actions, including delays in the release of the SARS-CoV-2 genome sequence and information about human-to-human spread of the virus.
  • Yes, but: "WHO experts genuinely thought Chinese scientists had done 'a very good job' in detecting and decoding the virus, despite the lack of transparency from Chinese officials," AP reported in June.

On the global scientific stage, transparency and data-sharing are key to science being verified and trusted.

  • Russia last week announced it had approved the world's first COVID-19 vaccine before completing phase 3 trials in humans and without publicly releasing data about the vaccine, a move that drew skepticism and criticism among scientists.
  • From China, CanSino Biologics and Sinopharm recently published results from Phase 1 and 2 trials of their vaccine in scientific journals.

Keep in mind: "So much of vaccine development is a game of chance," says Ryan Ritterson of Gryphon Scientific, a consulting firm that focuses on life sciences. "Failure doesn’t necessarily mean they aren’t where they need to be."

What to watch: Vaccine diplomacy is underway, with Pakistan, the Philippines and others entering deals for testing vaccines from China, per WSJ.

  • "A vaccine can be a channel for increasing influence, and the IOUs it builds up strategically around the world are intended to increase China’s prestige vis-a-vis the U.S.," says Fidler.

The bottom line: "If China is one of the first to develop a safe and effective vaccine, they would be in an extraordinary diplomatic and scientific moment in how they chose to share it," says Ritterson.

Iran's nuclear dilemma: Ramp up now or wait for Biden

The world is waiting to see whether Iran will strike back at Israel or the U.S. over the assassination of Mohsen Fakhrizadeh, the architect of Iran's military nuclear program.

Why it matters: Senior Iranian officials have stressed that Iran will take revenge against the perpetrators, but also respond by continuing Fakhrizadeh’s legacy — the nuclear program. The key question is whether Iran will accelerate that work now, or wait to see what President-elect Biden puts on the table.

Keep reading... Show less

U.K. clears Pfizer-BioNTech coronavirus vaccine for mass rollout

The United Kingdom became on Wednesday the first Western country in the world to license the Pfizer/BioNTech COVID-19 vaccine for widespread use.

What they're saying: "Today’s emergency use authorisation in the UK marks a historic moment in the fight against COVID-19," said Albert Bourla, the chairman and chief executive officer of Pfizer, per the Guardian.

  • "This authorisation is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the UK."

Editor's note: This a breaking news story. Please check back for updates.

Biden tells NYT he won't immediately remove U.S. tariffs on China

President Trump's 25% tariffs imposed on China under the phase one trade deal will remain in place at the start of the new administration, President-elect Biden said in an interview with the New York Times published early Wednesday.

Details: "I'm not going to make any immediate moves, and the same applies to the tariffs," Biden said. He plans to conduct a full review of the current U.S. policy on China and speak with key allies in Asia and Europe to "develop a coherent strategy," he said.

Keep reading... Show less

Trump threatens to veto Defense spending bill over social media shield

President Trump tweeted Tuesday a threat to veto a must-pass end-of-year $740 billion bill defense-spending authorization bill unless Conress repeals a federal law that protects social media sites from legal liability.

Why it matters: Trump's attempt to get Congress to end the tech industry protections under Section 230 of the Communications Decency Act is the latest escalation in his war on tech giants over what he and some other Republicans perceive as bias against conservatives.

Keep reading... Show less

The walls close in on Trump

With Bill Barr's "Et tu, Brute!" interview with AP, President Trump is watching the walls close in on his claims of fraud, hoaxes and conspiracies.

Why it matters: Trump and his legal team continue to claim election fraud. But the Republican governors of Arizona and Georgia have certified their elections, a loyalist like Barr has weighed in, and lower-ranking officials have taken potshots.

Keep reading... Show less

Congress plots COVID pandemic-era office upgrades

The House plans to renovate members' suites even though staff are worried about an influx of contractors and D.C. is tightening restrictions on large gatherings, some staffers told Axios.

Why it matters: The Capitol has been closed to public tours since March. Work over the holiday season comes as U.S. coronavirus cases spike, Americans beg for more pandemic assistance and food lines grow.

Keep reading... Show less

Trump applies extreme pressure on Bill Barr to release so-called Durham Report

President Trump and his allies are piling extreme pressure on Attorney General Bill Barr to release a report that Trump believes could hurt perceived Obama-era enemies — and view Barr's designation of John Durham as special counsel as a stall tactic, sources familiar with the conversations tell Axios.

Why it matters: Speculation over Barr's fate grew on Tuesday, with just 49 days remaining in Trump's presidency, after Barr gave an interview to the Associated Press in which he said the Justice Department has not uncovered evidence of widespread fraud that could change the election's outcome.

Keep reading... Show less

CDC to cut guidance on quarantine period for coronavirus exposure

The CDC will soon shorten its guidance for quarantine periods following exposure to COVID-19, AP reported Tuesday and Axios can confirm.

Why it matters: Quarantine helps prevent the spread of the coronavirus, which can occur before a person knows they're sick or if they're infected without feeling any symptoms. The current recommended period to stay home if exposed to the virus is 14 days. The CDC plans to amend this to 10 days or seven with a negative test, an official told Axios.

  • The CDC did not immediately respond to a request for comment.

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories